Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels
SARS-CoV-2 infection was shown to induce proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels in sepsis. Here, we investigate the association between serum PCSK9 levels and disease severity. PCSK9 was measured in serum of 55 controls, 40 patients with moderate and 60 patients with sev...
Saved in:
Main Authors: | Patricia Mester (Author), Pablo Amend (Author), Stephan Schmid (Author), Jürgen J. Wenzel (Author), Marcus Höring (Author), Gerhard Liebisch (Author), Sabrina Krautbauer (Author), Martina Müller (Author), Christa Buechler (Author), Vlad Pavel (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
by: Bianca E. Suur, et al.
Published: (2022) -
The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
by: Eun Ji Kim, et al.
Published: (2020) -
Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations
by: Fengyuan Lu, et al.
Published: (2024) -
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022) -
Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review
by: Wei C. Yuet, et al.
Published: (2021)